- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Apnimed, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| Di | Apnimed, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Di | Apnimed, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| APNIMED Aktie jetzt für 0€ handeln | |||||
| Di | Apnimed, Inc. reports Q2 results | 1 | Seeking Alpha | ||
| Di | Apnimed, Inc.: Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update | 153 | GlobeNewswire (Europe) | U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi- and assigned a PDUFA target action date of February 28,- 2027 If approved, Oxnimbi... ► Artikel lesen | |
| 04.09. | Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 25.08. | Apnimed rises on Street initiations following IPO | 1 | Seeking Alpha | ||
| 25.08. | Cantor Fitzgerald initiates Apnimed stock with overweight rating | 1 | Investing.com | ||
| 25.08. | BofA initiates Apnimed stock with buy rating on sleep apnea drug | 1 | Investing.com | ||
| 03.08. | Apnimed erzielt 220,8 Mio. US-Dollar bei NASDAQ-Börsengang | 1 | Investing.com Deutsch | ||
| 03.08. | Apnimed closes $220.8 million IPO on Nasdaq | 1 | Investing.com | ||
| 03.08. | Apnimed, Inc.: Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | 349 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization... ► Artikel lesen | |
| 03.08. | Apnimed, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.08. | Apnimed's IPO Bags $192M for What Could Become the First Oral Sleep Apnea Drug | 5 | MedCity News | ||
| 31.07. | Apnimed, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 31.07. | Sleep drug developer Apnimed rises on trading debut | 1 | Seeking Alpha | ||
| 31.07. | Sanofi to 'rebuild trust' with Regeneron; Apnimed adds to string of 'upsized' biotech IPOs | 32 | BioPharma Dive | ||
| 31.07. | Sleep apnea pill developer Apnimed prices upsized IPO at $16, the high end of the range | 9 | Renaissance Capital | ||
| 31.07. | Apnimed IPO raises $192m, as three other biotechs set terms | 1 | pharmaphorum | ||
| 31.07. | Apnimed's IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch | 1 | FierceBiotech |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 37,045 | -0,15 % | Novo Nordisk machte GLP-1 zum Milliardenmarkt, CAR-T die Krebsmedizin - welche Biotech-Plattform kommt als Nächstes? | ||
| VIATRIS | 14,252 | +0,07 % | Dividendenbekanntmachungen (21.08.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0642 EUR ALLISON TRANSMISSION HOLDINGS INC US01973R1014 0,29 USD 0,2483 EUR AMGEN... ► Artikel lesen | |
| SYNBIOTIC | 1,000 | -1,77 % | Original-Research: SYNBIOTIC SE (von NuWays AG): Under review | Original-Research: SYNBIOTIC SE - from NuWays AG
24.08.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for... ► Artikel lesen | |
| INCYTE | 105,35 | +0,52 % | Cantor Fitzgerald reiterates Neutral on Incyte stock after conference | ||
| ASSEMBLY BIOSCIENCES | 25,800 | +0,39 % | Assembly Biosciences zieht Milliarden-Option: Countdown auf den 15. Oktober gestartet | Bei Assembly Biosciences spitzt sich die Investmentstory deutlich zu. Mein Biotech-Favorit hat gegenüber seinem Pharmapartner Gilead seine Option ausgeübt, sich mit 40 Prozent an den US-Entwicklungskosten... ► Artikel lesen | |
| BIONANO GENOMICS | 1,230 | +0,82 % | MolDX proposes Medicare coverage for Bionano genome mapping test | ||
| NEKTAR THERAPEUTICS | 59,90 | -0,47 % | Nektar Therapeutics Announces Second Quarter 2026 Financial Results | SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,688 | +2,84 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update | AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| ALTIMMUNE | 2,850 | +1,24 % | Altimmune, Inc: Altimmune Announces Second Quarter 2026 Financial Results and Business Update | Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash... ► Artikel lesen | |
| JAGUAR HEALTH | 0,312 | -0,64 % | Jaguar Health, Inc.: All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease with Intestinal Failure | Continuation of treatment with blinded doses of crofelemer in the extension phase of the trial will support company's plans to file an NDA in mid-2027 for MVID, an ultrarare pediatric disease SAN FRANCISCO... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| ORION | 78,45 | +0,06 % | ORION Corp. Reports Higher Revenue And Profit In Q2 2026 | SEOUL (dpa-AFX) - ORION Corp. (271560.KS) on Friday reported revenue of KRW 893.59 billion for the second quarter of 2026, compared with KRW 777.17 billion in the same period of 2025. For the... ► Artikel lesen | |
| CAMURUS | 51,85 | -0,19 % | CAMURUS AB: Camurus' Nomination Committee appointed for the Annual General Meeting 2027 | ||
| WAVE LIFE SCIENCES | 4,000 | +1,14 % | Wave Life Sciences Ltd.: Wave Life Sciences Announces Completion of Redomiciliation to Delaware | CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 2,895 | -1,53 % | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System | HOPE is the first Interventional Psychiatry network to deploy Zeta Surgical's newly FDA-cleared TMS Robotic System; the HOPE clinical team is completing orientation and training at Zeta Surgical's... ► Artikel lesen |
Das Unternehmen APNIMED INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,27 % bei einem Aktienkurs von 26,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APNIMED INC finden Sie auf Wallstreet Online.